Anti-Dxd [12G9-2]

Description:

Recombinant monoclonal antibody to Dxd. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 12G9-2.

Clone Name:

12G9-2

Published Application(s):

ELISA

Published Species Reactivity:

Species independent

Products based on this clone:

{{heading}}

Please Select

Ab04094-23.0 Anti-Dxd [12G9-2]
Species independent
Rabbit IgG
Purified
Ships in 5-6 weeks

Ab04094-1.1 Anti-Dxd [12G9-2]
Species independent
Mouse IgG1
Purified
Ships in 5-6 weeks

Ab04094-10.0 Anti-Dxd [12G9-2]
Species independent
Human IgG1
Purified
Ships in 5-6 weeks

Ab04094-10.3 Anti-Dxd [12G9-2]
Species independent
Human IgG1
Fc Silent™
Purified
Ships in 5-6 weeks

Alternative Name(s) of Target: Exatecan derivative; Camptothecin analog
Immunogen: The original antibody was generated by immunizing BALB/c mice with Dxd-KLH conjugate.

Specificity: This antibody binds Dxd, an anti-cancer alkaloid camptothecin analog, which is a potent DNA topoisomerase I (TOP1) inhibitor. By forming a stable ternary complex with TOP1 and DNA, it arrests the cell cycle to S phase, thereby preventing DNA replication and causing cell death. DxD is used for the generation of antibody-drug conjugates for targeted delivery of toxic materials to cancerous cells. A HER2 targeting -DxD drug conjugate (DS-8201a) shows potent antitumor activity in HER2-positive models

Application Notes: The binding reactivity of this antibody towards Dxd-KLH and Dxd-BSA conjugates was determined using ELISA. This antibody is capable of binding antibody-drug conjugates ADC-8201 and ADC029 in a competitive ELISA, wherein the antibody was trastuzumab. The binding affinity of this antibody towards Dxd-BSA was determined using surface plasmon resonance (SPR) and it was reported to be Kd= 3.38nM (CN115677857).

Antibody first published in: PMID: